Current Document Type: HighlightsVideoPage MDS and Oligoblastic AML New Data on Eprenetapopt and Azacitidine - JADPRO

Watch More Highlights

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Anschutz Medical Campus, discusses findings from a long-term follow-up of the combination of eprenetapopt and azacitidine in patients with TP53-mutant myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia (AML). This is especially important information for advanced practitioners, given the fact that these gene mutations are found in up to 20% of patients with MDS or AML and 30% to 40% of treatment-related MDS/AML cases, representing a distinct molecular cohort with poor outcomes (Abstract 246).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.